Differential patterns of allelic loss in estrogen receptor‐positive infiltrating lobular and ductal breast cancer

The two main histological types of infiltrating breast cancer, lobular (ILC) and the more common ductal (IDC) carcinoma are morphologically and clinically distinct. To assess the molecular alterations associated with these breast cancer subtypes, we conducted a whole‐genome study of 166 archival estrogen receptor (ER)‐positive tumors (89 IDC and 77 ILC) using the Affymetrix GeneChip® Mapping 10K Array to identify sites of loss of heterozygosity (LOH) that either distinguished, or were shared by, the two phenotypes. We found single nucleotide polymorphisms (SNPs) of high‐frequency LOH (>50%) common to both ILC and IDC tumors predominately in 11q, 16q, and 17p. Overall, IDC had a slightly higher frequency of LOH events across the genome than ILC (fractional allelic loss = 0.186 and 0.156). By comparing the average frequency of LOH by chromosomal arm, we found IDC tumors with significantly (P < 0.05) higher frequency of LOH on 3p, 5q, 8p, 9p, 20p, and 20q than ILC tumors. We identified additional chromosomal arms differentiating the subtypes when tumors were stratified by tumor size, mitotic rate, or DNA content. Of 5,754 informative SNPs (>25% informativity), we identified 78 and 466 individual SNPs with a higher frequency of LOH (P < 0.05) in ILC and IDC tumors, respectively. Hierarchical clustering of these 544 SNPs grouped tumors into four major groups based on their patterns of LOH and retention of heterozygosity. LOH in chromosomal arms 8p and 5q was common in higher grade IDC tumors, whereas ILC and low‐grade IDC grouped together by virtue of LOH in 16q. Published 2008 Wiley‐Liss, Inc.

[1]  S. Hsu,et al.  The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. , 1981, American journal of clinical pathology.

[2]  H. Kuniyasu,et al.  Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma , 2005, Oncogene.

[3]  P. Rabinovitch,et al.  Cytokeratin labeling of breast cancer cells extracted from paraffin-embedded tissue for bivariate flow cytometric analysis. , 1996, Cytometry.

[4]  W. Bodmer,et al.  THE FREQUENCY AND MECHANISM OF LOSS OF HETEROZYGOSITY ON CHROMOSOME 11q IN BREAST CANCER , 1996, The Journal of pathology.

[5]  Stefan Handt,et al.  Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization , 2001, The Journal of pathology.

[6]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[7]  R Anbazhagan,et al.  Allelic loss of chromosomal arm 8p in breast cancer progression. , 1998, The American journal of pathology.

[8]  Funda Meric-Bernstam,et al.  BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. , 2006, Cancer cell.

[9]  S. Devries,et al.  Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma , 2004, Cancer.

[10]  P. Porter,et al.  Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. , 1999, Journal of the National Cancer Institute.

[11]  P. Porter,et al.  Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. , 2003, JAMA.

[12]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[13]  R. Cote,et al.  Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques , 1994, Human pathology.

[14]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[15]  P. Newcomb,et al.  Hormone replacement therapy in relation to breast cancer. , 2002, JAMA.

[16]  S. Ichihara,et al.  Loss of heterozygosity and microsatellite instability in ductal carcinoma in situ of the breast. , 2000, Cancer letters.

[17]  Lei Xu,et al.  GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H Buerger,et al.  Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes , 1999, The Journal of pathology.

[19]  David Botstein,et al.  Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. , 2004, Molecular biology of the cell.

[20]  Jane Fridlyand,et al.  Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. , 2003, Cancer research.

[21]  David J. Chen,et al.  Requirement for XRCC4 and DNA ligase IV in alignment-based gap filling for nonhomologous DNA end joining in vitro. , 2003, Cancer research.

[22]  Ajay N. Jain,et al.  Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.

[23]  Xingzhi Xu,et al.  Microcephalin Is a DNA Damage Response Protein Involved in Regulation of CHK1 and BRCA1*♦ , 2004, Journal of Biological Chemistry.

[24]  A. Thor,et al.  Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas , 1996, Science.

[25]  Cheng Li,et al.  dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data , 2004, Bioinform..

[26]  C. Croce,et al.  Loss of heterozygosity at 11q22-q23 in breast cancer. , 1994, Cancer research.

[27]  O. Pereira-smith,et al.  Primary and Compensatory Roles for RB Family Members at Cell Cycle Gene Promoters That Are Deacetylated and Downregulated in Doxorubicin-Induced Senescence of Breast Cancer Cells , 2006, Molecular and Cellular Biology.

[28]  E. Gabrielson,et al.  Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. , 1996, Cancer research.

[29]  B. Anderson,et al.  Trends in incidence rates of invasive lobular and ductal breast carcinoma. , 2003, JAMA.

[30]  G. Hortobagyi,et al.  Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Yıldırım,et al.  Is invasive lobular carcinoma different from invasive ductal carcinoma? , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[32]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[33]  A. Jaiswal,et al.  Involvement of adenomatous polyposis coli in colorectal tumorigenesis. , 2005, Frontiers in bioscience : a journal and virtual library.

[34]  H. Poulsen,et al.  Immunohistochemical estrogen receptor determination in paraffin‐embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer , 1989, Cancer.

[35]  P. Porter,et al.  Relationship between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-Lobular Breast Carcinomas , 2008, Cancer Epidemiology Biomarkers & Prevention.

[36]  Junko Oshima,et al.  WRN, the protein deficient in Werner syndrome, plays a critical structural role in optimizing DNA repair , 2003, Aging cell.

[37]  C. Aldaz,et al.  WWOX, a chromosomal fragile site gene and its role in cancer. , 2006, Advances in experimental medicine and biology.

[38]  N. Carter,et al.  A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH , 2006, Oncogene.

[39]  David L. Page,et al.  Diagnostic Histopathology of the Breast , 1988 .

[40]  M. Vijver,et al.  E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. , 1995, The EMBO journal.

[41]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[42]  G. Zachos,et al.  Chk1 Requirement for High Global Rates of Replication Fork Progression during Normal Vertebrate S Phase , 2006, Molecular and Cellular Biology.

[43]  Shane Herbert,et al.  Whole genome SNP arrays using DNA derived from formalin‐fixed, paraffin‐embedded ovarian tumor tissue , 2005, Human mutation.

[44]  P. Devilee,et al.  Somatic genetic changes in human breast cancer. , 1994, Biochimica et biophysica acta.

[45]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[46]  Sridhar Ramaswamy,et al.  Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers , 2004, Cancer Research.

[47]  Barbara J. Trask,et al.  Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes , 2004, Cancer Research.

[48]  C. Counter,et al.  Characterization of Interactions between PinX1 and Human Telomerase Subunits hTERT and hTR* , 2004, Journal of Biological Chemistry.

[49]  K. Rogers,et al.  Immunohistological demonstration of progesterone receptor in breast carcinomas: correlation with radioligand binding assays and oestrogen receptor immunohistology. , 1988, Journal of clinical pathology.

[50]  R. Elledge,et al.  Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome , 2004, Breast Cancer Research.

[51]  A. Hanby,et al.  Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. , 1999, Cancer research.

[52]  W. Willett,et al.  Breast cancer (1) , 1992, The New England journal of medicine.